Assembly Bill A2904

Signed By Governor
2019-2020 Legislative Session

Prohibits certain insurance policies from requiring prior authorization for certain medications used in the treatment of substance use disorders; repealer

download bill text pdf

Sponsored By

Archive: Last Bill Status - Signed by Governor

  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions
Votes

co-Sponsors

multi-Sponsors

2019-A2904 (ACTIVE) - Details

See Senate Version of this Bill:
S4808
Law Section:
Insurance Law
Laws Affected:
Amd §§3216, 3221 & 4303, rpld §3216 sub§ (i) ¶31-a, §3221 sub§ (l) ¶¶7-a & 7-b, §4303 sub§§ (l-1) & (l-2), Ins L
Versions Introduced in 2017-2018 Legislative Session:
A7979, S6674

2019-A2904 (ACTIVE) - Summary

Prohibits certain insurance policies from requiring prior authorization for buprenorphine products, methadone and long acting injectable naltrexone for detoxification or maintenance treatment of substance use disorders.

2019-A2904 (ACTIVE) - Bill Text download pdf 

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   2904
 
                        2019-2020 Regular Sessions
 
                           I N  A S S E M B L Y
 
                             January 28, 2019
                                ___________
 
 Introduced  by M. of A. QUART -- read once and referred to the Committee
   on Insurance
 
 AN ACT to amend the insurance law, in relation  to  prohibiting  certain
   insurance  policies  from  requiring  prior  authorization for certain
   medications used in the treatment of substance use disorders;  and  to
   repeal certain provisions of such law relating thereto
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Paragraph 31-a of subsection (i) of  section  3216  of  the
 insurance  law  is REPEALED and a new paragraph 31-a is added to read as
 follows:
   (31-A) (A) NO POLICY THAT PROVIDES MEDICAL, MAJOR MEDICAL  OR  SIMILAR
 COMPREHENSIVE-TYPE COVERAGE AND PROVIDES COVERAGE FOR PRESCRIPTION DRUGS
 FOR  MEDICATION  FOR  THE  TREATMENT  OF  A SUBSTANCE USE DISORDER SHALL
 REQUIRE PRIOR AUTHORIZATION FOR AN INITIAL OR RENEWAL  PRESCRIPTION  FOR
 ALL BUPRENORPHINE PRODUCTS, METHADONE OR LONG ACTING INJECTABLE NALTREX-
 ONE  FOR  DETOXIFICATION  OR  MAINTENANCE  TREATMENT  OF A SUBSTANCE USE
 DISORDER EXCEPT WHERE OTHERWISE PROHIBITED BY LAW.
   (B) COVERAGE PROVIDED UNDER THIS PARAGRAPH MAY BE  SUBJECT  TO  COPAY-
 MENTS,  COINSURANCE,  AND  ANNUAL  DEDUCTIBLES  THAT ARE CONSISTENT WITH
 THOSE IMPOSED ON OTHER BENEFITS WITHIN THE POLICY.
   § 2. Paragraphs 7-a and 7-b of subsection (l) of section 3221  of  the
 insurance  law  are REPEALED and a new paragraph 7-a is added to read as
 follows:
   (7-A) (A) EVERY POLICY THAT PROVIDES MEDICAL, MAJOR MEDICAL OR SIMILAR
 COMPREHENSIVE-TYPE LARGE GROUP COVERAGE SHALL PROVIDE IMMEDIATE COVERAGE
 FOR ALL BUPRENORPHINE PRODUCTS,  METHADONE  OR  LONG  ACTING  INJECTABLE
 NALTREXONE WITHOUT PRIOR AUTHORIZATION FOR THE DETOXIFICATION OR MAINTE-
 NANCE TREATMENT OF A SUBSTANCE USE DISORDER.

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD01428-01-9

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.